NCT04894253

Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus

Study of the Immune Response to SARS-CoV-2 Vaccination in Patients With Systemic Lupus

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 7 (actual)
• Sponsor: University Hospital, Strasbourg, France · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in a lupus population. The secondary objective is to study the impact of lupus disease activity on the humoral and cellular response of patients following vaccination against SARS-CoV-2. The hypothesis is that disease activity and / or certain treatments used in lupus may interfere with the humoral and cellular immune response induced by vaccination against SARS-CoV-2.

Conditions

• Systemic Lupus

Interventions

Type	Name	Description
BIOLOGICAL	SRAS-CoV-2 vaccination immunological response	Follow for 18 months a single group of 30 patients with systemic lupus after their SRAS-CoV-2 vaccination. Intervention includes immunological analysis on additional volume of blood collected as part of routine care.

Timeline

• Start date: 2021-06-07
• Primary completion: 2021-06-07
• Completion: 2023-12-22
• First posted: 2021-05-20
• Last updated: 2025-12-23

Locations

1 site across 1 country: France